JXJingjing Xu

Jingjing Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jingjing Xu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Na Wei

    Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Chao Chen

    Department of Pathology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian She Dong Avenue, Zhengzhou, China

    1 shared publication
  • Chaoyang Zhang

    Department of Emergency, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

    1 shared publication
  • Chenguang Liu

    Department of Pathology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian She Dong Avenue, Zhengzhou, China

    1 shared publication
  • Feng Li

    Department of Orthopedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China

    1 shared publication
  • Gang Dong

    Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, No. 1 Jian She Dong Avenue, Zhengzhou, China

    1 shared publication

Latest Publications

  • Open Access

    Effects of Adjuvant Radiation Plus Chemotherapy on Survival Outcomes in Stage III C Endometrial Cancer According to Histology: Analysis of Data from the Surveillance, Epidemiology, and End Results Database

    by Junna Kou, Guangwei Yan, Lin Xiao, Na Wei, Huayan Ren, Jingjing Xu

    Purpose: To evaluate the survival benefit of radiation plus chemotherapy in adult females with stage IIIC endometrial cancer and to investigate whether the benefit varies according to histology. Methods: Data from adult females with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC endometrial cancer, who underwent at least total hysterectomy between 2010 and 2015, were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Adjuvant treatments were categorized as chemotherapy alone, chemotherapy with external beam radiation therapy (EBRT), chemotherapy with vaginal brachytherapy (VBT), or chemotherapy with EBRT+VBT. Multivariate Cox regression models, Kaplan–Meier curves, and log-rank tests were used to assess the association between treatment modality and overall survival (OS). Results: In total, 2138 cases were identified: stage IIIC1 (n = 1299 [60.8%]) and stage IIIC2 (n = 839 [39.2%]). Median OS for all patients was 48 (interquartile range [IQR] 28-70) months. Regarding adjuvant treatment, 40.5% of patients underwent chemotherapy only, followed by chemotherapy with EBRT (35.5%). Stage IIIC patients treated with chemotherapy plus radiation exhibited a significantly reduced risk for death from endometrial cancer in both univariate and multivariate analyses ( P < 0.001). However, when stratified according to histology, OS also differed according to treatment modality when analyzing each histological type; combination therapy was no longer significantly different from chemotherapy alone for any histology (clear cell and carcinosarcoma). Combination therapy was associated with improved OS in patients with IIIC1 and IIIC2 disease. Similar associations were observed in patients with high-grade stage IIIC endometrioids. However, for low-grade tumors, combination therapy was no longer associated with reduced risk for death compared with chemotherapy alone. Conclusion: For patients with stage IIIC endometrial cancer, combined treatment with radiation and chemotherapy was associated with improved OS compared with chemotherapy alone. However, no survival benefit was found, and radiotherapy may be unnecessary in patients with low-grade endometrioids.


  • Open Access

    ciRS‐7 Promotes the Proliferation and Migration of Papillary Thyroid Cancer by Negatively Regulating the miR‐7/Epidermal Growth Factor Receptor Axis

    by Jun-Ya Han, Si Guo, Na Wei, Rui Xue, Wencai Li, Gang Dong, Jianhua Li, Xiangyu Tian, Chao Chen, Sen Qiu, et al.

    Purpose. The incidence of papillary thyroid cancer (PTC) is increasing, and traditional diagnostic methods are unsatisfactory. Therefore, identifying novel prognostic markers is very important. ciRS‐7 has been found to play an important role in many cancers, but its role in PTC has not been reported. This study was performed to evaluate the biological role and mechanism of ciRS‐7 in PTC. Material and Methods. The expression of ciRS‐7 in PTC tissues and the matched adjacent tissues was determined by quantitative reverse transcription polymerase chain reaction (qRT‐PCR). The PTC cell lines (TPC‐1 and BCPAP) were used to evaluate the role of ciRS‐7. ciRS‐7‐siRNA and overexpression plasmid were constructed and transfected into PTC cells. A CCK‐8 assay and colony formation assay were performed to explore the effects of ciRS‐7 on cell proliferation. Annexin V/PI staining and FACS detection were used to detect cell apoptosis. Wound healing assay was performed to detect cell migration. A transwell assay was conducted to explore the effects of ciRS‐7 on invasion and migration. Western blotting was performed to evaluate protein expression. The luciferase reporter system was used to determine the underlying mechanism of miR‐7. Result. ciRS‐7 was highly expressed in PTC tissues and cell lines compared with the corresponding controls. In vitro study showed that ciRS‐7 silencing suppressed proliferation, migration, and invasion of TPC‐1 and BCPAP. Mechanistically, the effects of ciRS‐7 on invasion and migration may be related to epithelial‐mesenchymal transition (EMT). ciRS‐7 silencing could attenuate effects on PTC cells induced by miR‐7 knockdown. Epidermal growth factor receptor (EGFR), which was demonstrated to be a target of miR‐7, decreased significantly in ciRS‐7‐siRNA PTC cells. Overexpression of EGFR also attenuated effects of PTC cells induced by silencing ciRS‐7. Conclusion. ciRS‐7 was significantly upregulated in PTC tissues, and it promoted the progression of PTC by regulating the miR‐7/EGFR axis. ciRS‐7 is a promising prognostic biomarker and therapeutic target in PTC.